Cyclooxygenase-2 inhibitor-associated acute renal failure: Case report with rofecoxib and review of the literature

Pharmacotherapy

Volumn 22, Issue 10, 2002, Pages 1317-1321

  Morales, Enid ^a   Mucksavage, Jeffrey J ^b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ALLOPURINOL; ATENOLOL; ATORVASTATIN; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIGOXIN; FUROSEMIDE; INDOMETACIN; LOSARTAN; METOLAZONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN E2; ROFECOXIB; WARFARIN; CYCLOOXYGENASE 2; ISOENZYME; LACTONE; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; SULFONE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTHRITIS; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; EDEMA; ERYTHEMA MULTIFORME; FEMALE; FLUID BALANCE; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; GOUT; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; OSTEOARTHRITIS; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SODIUM DEPLETION; TOXIC EPIDERMAL NECROLYSIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; REVIEW;

AGED; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOENZYMES; KIDNEY FAILURE, ACUTE; LACTONES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 0036794043     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.15.1317.33472     Document Type: Article

References (35)

1. Simon LS, Weaver DY, Graham AJ, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999;282:1921-8.
2. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
3. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double blind comparison. Lancet 1999;354:2106-11.
4. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
5. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
6. Day R, Morrison B, Leiza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7.
7. Cryer B, Kimmey M. Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1998;105(1B):20S-30.
8. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99.
9. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-72.
10. Schlondroff D. Renal complications of nonsteroidal antiinflammatory drugs. Kidney Int 1993;44:643-53.
11. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996;156:2433-9.
12. Schneider A, Stahl RAK. Cyclooxygenase-2 (COX-2) and the kidney: current status and potential perspectives. Neprol Dial Transplant 1998;13:10-12.
13. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999;107(6A):65S-71.
14. Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000;160:913-20.
15. Harris RC, Mckanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases salt restriction. J Clin Invest 1994;94:2504-10.
16. Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1997;274:F481-9.
17. Vio CP, Cespedes C, Gallardo P, Masferrer JL. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997;30(pt 2):687-92.
18. Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997;272(4 pt 2):F460-8.
19. Catella-Lawson F, Mcadam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-41.
20. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160:1465-70.
21. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low salt diet. A randomized controlled trial. Ann Intern Med 2000;133:1-9.
22. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66:76-84.
23. Zhao SZ, Renolds MW, Lefkowith J, Whelton A, Arellano FM. Comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre Safety Database. Clin Therap 2001;23:1478-91.
24. Perazella MA, Eras J. Are COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000;35:937-40.
25. Wolf G, Porth J, Stahl RA. Acute renal failure associated with rofecoxib [letter]. Ann Intern Med 2000;133:394.
26. Lamb RV, Walton T. Acute renal failure after administration of losartan [letter]. West Virg Med J 1996;92:241.
27. Osterman M, Goldsmith DJ, Doyle T, Kingswood JC, Sharpstone P. Reversible acute renal failure induced by losartan in a renal transplant recipient. Post Grad Med J 1997;73:105-7.
28. Mills RM. Severe hypersensitivity reactions associated with allopurinol. JAMA 1971;216:799-802.
29. Young JL, Boswell RB, Nies AS. Severe allopurinol hypersensitivity association with thiazides and prior renal compromise. Arch Intern Med 1974;134:553-8.
30. Pluim HJ, VanDeuren M, Wetzels JF. The allopurinol hypersensitivity syndrome. Netherlands J Med 1998;52:107-10.
31. Kumar A, Edward N, White NI, Johnston PW, Catto GR. Lesson of the week: allopurinol, erythema multiforme, and renal insufficiency. BMJ 1996;312:173-4.
32. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993;27:337-43.
33. Pfizer Inc. Celebrex (celecoxib) package insert. New York, NY; 2000.
34. Merck & Co., Inc. Vioxx (rofecoxib) package insert. West Point, PA; 2001.
35. Pharmacia Corporation. Bextra (valdecoxib) package insert. Chicago, IL; 2002.